L’Oréal US settles hair relaxer cancer claims lawsuit

In the first case of its kind to go to trial, L’Oréal’s US subsidiary reached a settlement with four women who claimed that the use of chemical hair relaxers contributed to their development of gynaecological cancers

You need to be a subscriber to read this article.
Click here to find out more.

L’Oréal’s US subsidiary has agreed to a settlement in a lawsuit which claimed that chemicals in hair relaxer products contributed to the development of cancer.

In a statement provided to Cosmetics Business, a L’Oréal USA spokesperson said: “Our highest priority is the health and wellbeing of all our consumers. 

“Our products are subject to a rigorous scientific evaluation of their safety by experts who also ensure that we strictly follow all regulations in every market in which we operate. 

“We stand by the safety of SoftSheen-Carson's products.”

The four plaintiffs in the case had claimed that the use of chemical hair relaxers contributed to their development of gynaecological cancers.

The lawsuit was the first to reach trial in the US related to allegations of cancer risks associated with hair relaxer products.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.

Subscribe now Already a subscriber? Sign in here.

You may also like